中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2011年
1期
18-20
,共3页
汪玉芳%柯冬云%冯佩珠%罗家琼%谭俐
汪玉芳%柯鼕雲%馮珮珠%囉傢瓊%譚俐
왕옥방%가동운%풍패주%라가경%담리
降脂排卵方%多囊卵巢综合征%脂质代谢相关因子%调控
降脂排卵方%多囊卵巢綜閤徵%脂質代謝相關因子%調控
강지배란방%다낭란소종합정%지질대사상관인자%조공
Lipid-lowering ovulation Decoction%Polycystic ovarian syndrome%Lipid metabolism related factors%Regulation
目的 研究降脂排卵方在多囊卵巢综合征治疗过程中对配体激活的核受体超家族转录因子(PPARα)、过氧化物酶体增殖物激活受体γ辅助活化因子(PGC-1α)及含有"碱性螺旋-环-螺旋-亮氨酸拉链"结构的核转录因子(SREBP-1c)、固醇调节元件结合蛋白裂解激活蛋白(SCAP)的调控作用.方法 选择多囊卵巢综合征患者84例随机分为中药治疗组、西药治疗组、中西医结合治疗组,中药治疗组采用降脂排卵方治疗,西药治疗组服用炔雌醇环丙孕酮片3个周期,中西医结合治疗组则同时采用中药治疗组和西药治疗组方法联合治疗.观察各组治疗前后脂质代谢相关因子的变化.结果 中西医结合治疗组可以显著提高PPARα、PGC-1α及降低SREBP-1c、SCAP拷贝数,可以显著降低体质量指数,中药组次之,而西药组则对脂质代谢相关因子及体质量指数的调控作用不明显.三组月经改善总有效率分别为71.42%、75.00%、92.86%.结论 降脂排卵方对多囊卵巢综合征患者脂质代谢相关因子PPARα、PGC-1α及SREBP-1c、SCAP有明显调控作用.
目的 研究降脂排卵方在多囊卵巢綜閤徵治療過程中對配體激活的覈受體超傢族轉錄因子(PPARα)、過氧化物酶體增殖物激活受體γ輔助活化因子(PGC-1α)及含有"堿性螺鏇-環-螺鏇-亮氨痠拉鏈"結構的覈轉錄因子(SREBP-1c)、固醇調節元件結閤蛋白裂解激活蛋白(SCAP)的調控作用.方法 選擇多囊卵巢綜閤徵患者84例隨機分為中藥治療組、西藥治療組、中西醫結閤治療組,中藥治療組採用降脂排卵方治療,西藥治療組服用炔雌醇環丙孕酮片3箇週期,中西醫結閤治療組則同時採用中藥治療組和西藥治療組方法聯閤治療.觀察各組治療前後脂質代謝相關因子的變化.結果 中西醫結閤治療組可以顯著提高PPARα、PGC-1α及降低SREBP-1c、SCAP拷貝數,可以顯著降低體質量指數,中藥組次之,而西藥組則對脂質代謝相關因子及體質量指數的調控作用不明顯.三組月經改善總有效率分彆為71.42%、75.00%、92.86%.結論 降脂排卵方對多囊卵巢綜閤徵患者脂質代謝相關因子PPARα、PGC-1α及SREBP-1c、SCAP有明顯調控作用.
목적 연구강지배란방재다낭란소종합정치료과정중대배체격활적핵수체초가족전록인자(PPARα)、과양화물매체증식물격활수체γ보조활화인자(PGC-1α)급함유"감성라선-배-라선-량안산랍련"결구적핵전록인자(SREBP-1c)、고순조절원건결합단백렬해격활단백(SCAP)적조공작용.방법 선택다낭란소종합정환자84례수궤분위중약치료조、서약치료조、중서의결합치료조,중약치료조채용강지배란방치료,서약치료조복용결자순배병잉동편3개주기,중서의결합치료조칙동시채용중약치료조화서약치료조방법연합치료.관찰각조치료전후지질대사상관인자적변화.결과 중서의결합치료조가이현저제고PPARα、PGC-1α급강저SREBP-1c、SCAP고패수,가이현저강저체질량지수,중약조차지,이서약조칙대지질대사상관인자급체질량지수적조공작용불명현.삼조월경개선총유효솔분별위71.42%、75.00%、92.86%.결론 강지배란방대다낭란소종합정환자지질대사상관인자PPARα、PGC-1α급SREBP-1c、SCAP유명현조공작용.
Objective To explore the effect of Jiangzhipailuan decoction in regulating PPARα( belong to the nuclear receptor family of ligand-activated transcription factors ), PGC- 1α ( peroxime proliferator activated releptour)and SREBP-1c( belong to the baichelix-loop-helix-leucine zipper class of transcription factors), SCAP( SREBP cleavage activating protein) related to lipid metabolism in the treatment of polycystic ovarian syndrome. Methods 84 patients suffered polycystic ovary syndrome were randomly divided into 4 groups: one received traditional Chinese medicine treatment, one western medicine treatment, one combination therapy and one as the control group. Traditional Chinese medicine group was treated with Jiangzhipailuan decoction treatment for 3 months, western medicine group was treated with up to Diane-35 ( ethinyl cyproterone tablets) for three cycles, while the combination therapy group was treated with traditional Chinese medicine ,western medicine as well as combined treatment for 3 courses. Results In the combination therapy group the PPARα, PGC-1α and decreased SREBP-1c, SCAP copy number was significantly improved ,and body mass index was significantly lowered. The total improvement rate of menstrual in three groups were 71.42% ,75.00% ,92.86% respectively. Conclusion Jiangzhipailuan decoction played a prominent role in regulating PPARα,PGC-1α and SREBP-1c,SCAP related to lipid metabolism in the treatment of polycystic ovarian syndrome.
